Polykystose rénale autosomique dominante (French Wikipedia)

Analysis of information sources in references of the Wikipedia article "Polykystose rénale autosomique dominante" in French language version.

refsWebsite

Global rank French rank

2,374^th place

298^th place

234^th place

147^th place

3asnjournals.org

low place

8,208^th place

2,393^rd place

506^th place

4,489^th place

1,746^th place

1ahajournals.org

3,608^th place

659^th place

ahajournals.org

stroke.ahajournals.org

Rinkel GJ, Djibuti M, Algra A, van Gijn J, Prevalence and risk of rupture of intracranial aneurysms: a systematic review, Stroke, 1998;29:251-256

asnjournals.org

jasn.asnjournals.org

VE Torres, Water for ADPKD? Probably, yes, J Am Soc Nephrol, 2006;17;2089–2091
Pirson Y, Chauveau D, Torres V, Management of cerebral aneurysms in autosomal dominant polycystic kidney disease, J Am Soc Nephrol, 2002;13:269-276

cjasn.asnjournals.org

Chapman AB, Bost JE, Torres VE et al. Kidney volume and functional outcomes in autosomal dominant polycystic kidney disease, Clin J Am Soc Nephrol, 2012;7:479-486

karger.com

content.karger.com

E Higashihara, K Nutahara and M Kojima et al., Prevalence and renal prognosis of diagnosed autosomal dominant polycystic kidney disease in Japan, Nephron 80 (1998), pp. 421–427

nature.com

Gabow PA, Johnson AM, Kaehny WD et al. Factors affecting the progression of renal disease in autosomal-dominant polycystic kidney disease, Kidney Int, 1992;41:1311-1319
ZH Bajwa, KA Sial, AB Malik, TI Steinman, Pain patterns in patients with polycystic kidney disease, Kidney Int, 2004;66;1561–1569
(en) P Ruggenenti, A Remuzzi, P Ondei et al. « Safety and efficacy of long-acting somatostatin treatment in autosomal dominant polcysytic kidney disease » Kidney Int. 2005;68;206–216

nejm.org

nejm.org

Chapman AB, Johnson A, Gabow PA, Schrier RW, The renin-angiotensin-aldosterone system and autosomal dominant polycystic kidney disease, N Engl J Med, 1990;323:1091-1096
(en) Schrier RW, Abebe KZ, Perrone RD et al. « Blood pressure in early autosomal dominant polycystic kidney disease » N Engl J Med. 2014;371:2255-2266
(en) Torres VE, Chapman AB, Devuyst O et al. « Tolvaptan in patients with autosomal dominant polycystic kidney disease », N Engl J Med. 2012;367:2407-18.
(en) Walz G, Budde K, Mannaa M et al. « Everolimus in patients with autosomal dominant polycystic kidney disease » N Engl J Med. 2010;363:830-840 (Erratum, N Engl J Med. 2010;363:1190)

content.nejm.org

Grantham JJ, Autosomal dominant polycystic kidney disease, N Eng J Med, 2008;359:1477-1485
Grantham JJ, Torres VE, Chapman AB et als. Volume progression in polycystic kidney disease, N Engl J Med, 2006;354:2122-2130

thelancet.com

Hateboer N, van Dijk MA, Bogdanova N et als. Comparison of phenotypes of polycystic kidney disease types 1 and 2, Lancet, 1999;353:103-107
(en) Torres VE, Harris PC, Pirson Y. « Autosomal dominant polycystic kidney disease » Lancet. 2007;369;1287-1301